Medical Progress: How Far We’ve Come, But Still a Long Road Ahead

Q2 | July 2020

Topic: Human Interest

Devin Crago CFA

July 24, 2020

Image used with permission: iStock/SolStock


Print & Share

Print

Medical Progress: How Far We’ve Come, But Still a Long Road Ahead

Q2 | July 2020

A recent volume of the New England Journal of Medicine found its way to my reading pile last week.

The first article was titled “Four Decades of HIV/AIDS – Much Accomplished, Much to Do”.(1) One of the authors, interestingly, was A.S. Fauci… yes, that Anthony Fauci who has so frequently appeared in the media of late.

How does he find the time, one might ask? But that is another story.

Progress on HIV/AIDS

I decided to read the article partly because of the author, partly out of human interest, and partly because one of the requirements of successful investing is to read widely.

Another factor that piqued my interest is that one of our portfolio holdings – Gilead Sciences, Inc. – has been instrumental in driving forward the scientific understanding of the human immunodeficiency virus (HIV).(2) Gilead has developed 11 HIV medications, including several important “firsts”: the first single-pill regimen to treat HIV and the first drug to prevent HIV infection. Its drug, Biktarvy®, is the most prescribed HIV treatment in the U.S.

Since the acquired immunodeficiency syndrome (AIDS) was first recognized in 1981, the scientific progress in reducing the effects of the disease has been remarkable. Consider:

  • In 1981, the prognosis for life expectancy was a bleak 6-12 months. Now, life expectancy while receiving treatment is close to normal.
  • The risk of transmission to an uninfected sexual partner can now be managed with great effectiveness. A once-daily, single-pill drug regimen is 99% effective in preventing sexual acquisition of HIV infection by an at-risk uninfected person (Gilead produces two such drugs, Descovy® and Truvada®).
  • The United States’ flagship initiative named “The President’s Emergency Plan for AIDS Relief” has provided testing to 79.6 million people, delivered antiretroviral therapy to 15.7 million people and enabled the birth of 2.6 million uninfected babies to mothers with HIV.

All of this is progress, and it provides some optimism for the approximately 40 million people living with HIV.

Progress on COVID-19

We hope that the success that science has had with AIDS treatment may contain lessons for addressing COVID-19. In the current environment, finding reasons for optimism can be difficult; case counts are rising again in many parts of the world and the sheer scope of the disease makes it different from any other virus the modern world has seen.

Yet, while advances in AIDS treatment took many years, today there is hope that progress on the pharmaceutical front might bring about a faster solution for COVID-19. As of July, there are 166 vaccine candidates in development(3) and we expect pivotal data on many vaccine trials will arrive in the next few months. There is a lot at stake for all of us. But at Nexus we are watching the results from three leading vaccine candidates in particular:

  • The University of Oxford and AstraZeneca. Their vaccine, known as AZD1222, is considered the most advanced candidate. AstraZeneca has stated(4) that it is targeting “first deliveries” of the vaccine by September 2020. The most recent trial results show that participants who received the vaccine had significant immune responses for both antibodies (which may neutralize the virus) and T-cells (which can destroy cells that the virus invades).
  • Pfizer and their German partner BioNTech. The two companies ran trials of their vaccine candidate, BNT162b1, in both the U.S. and Germany and found it delivered high levels of neutralizing antibodies and elicited T-cell responses. Pfizer has been a long-standing holding in Nexus portfolios.
  • CanSino Biologics and the Beijing Institute of Biotechnology. A study of 508 volunteers found that this candidate, known as Ad5-nCoV, produced a strong immune response in the majority of the trial participants. Importantly, the trial was uncommon in that it included patients 55 years or older.

Unfortunately, there are no guarantees that these vaccines will work. If – as we all hope – they do, there are big milestones yet to be achieved on safety, effectiveness and determining the duration of the immune response.

What’s more, there are additional challenges to ensure sufficient quantities of vaccine can be manufactured, distributed and administered where it is needed around the world. There is no definitive answer on when any of these candidates might be broadly administered to people, but the consensus view is it won’t be until 2021.

Despite all of this uncertainty, we can draw some comfort that we are making progress in the fight against COVID-19. From an investor’s point of view(5), this progress is a welcome sign that the probability is rising that economies, industries and companies will recover from this crisis. There will likely be setbacks on the road ahead, but the medical progress appears to be heading in the right direction.

Borrowing from the title of Dr. Fauci’s article, much has been accomplished, but there remains much to do.

(1) “Four Decades of HIV/AIDS – Much Accomplished, Much to Do”, Anthony S. Fauci, M.D., and H. Clifford Lane, M.D., The New England Journal of Medicine, Vol. 383, No.1, July 2, 2020.
(2) Gilead has also been a leader in progressing the science around COVID-19. In July 2020, Gilead released data demonstrating that severely ill patients treated with its investigational drug, remdesivir, were 62% less likely to die than patients treated with standard care alone.
(3) https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
(4) https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-advances-response-to-global-covid-19-challenge-as-it-receives-first-commitments-for-oxfords-potential-new-vaccine.html
(5) Take the Long View: Coronavirus – The Investor’s Perspective

More Like This...

See another CRM2 blog post that may be of interest to you.

No posts found.

More Like This...

See another Foundations & Endowments blog post that may be of interest to you.

That Giving Feeling

Topic:
Foundations & Endowments, Tax Planning
Excerpt:
Summer is now a distant memory. In fact, a radio announcer declared only 77 days until Christmas. Ugh. It is usually in the last quarter of the year

More Like This...

See another Human Interest blog post that may be of interest to you.

What a World!

Topic:
Human Interest
Excerpt:
You don’t need to read a blog from your most trusted investment advisor to realize that 2020 might go down as one of the most notable and difficult

More Like This...

See another Inside Nexus blog post that may be of interest to you.

Swimming Naked

Topic:
Inside Nexus
Excerpt:
Warren Buffett has a wonderful line. “Only when the tide goes out do you discover who's been swimming naked.”

More Like This...

See another Investments blog post that may be of interest to you.

It’s a Topsy-Turvy Year: Investing During COVID

Topic:
Investments
Excerpt:
This year has been plenty weird. For starters, it feels like January was about five years ago… if you can remember it at all. Putting aside the health

More Like This...

See another Pearls of Wisdom blog post that may be of interest to you.

“Work, Work, Work, Work, Work, Work”

Topic:
Pearls of Wisdom
Excerpt:
This has been a busy year. I’ve had lots happening on the home front (a wedding!) and lots going on at the office (too long to list!) Managing work

More Like This...

See another Tax Planning blog post that may be of interest to you.

The (U.S.) Taxman Cometh

Topic:
Tax Planning
Excerpt:
Like the medical patient who expects to endure a fair bit of poking, probing and prodding from the doctor, clients of financial providers have had to

More Like This...

See another Wealth Planning blog post that may be of interest to you.

Estate Planning: Questions from our Virtual Chat

Topic:
Wealth Planning
Excerpt:
Helping clients with their estate planning is something we do here at Nexus. However, we are often involved in identifying the best tools for the

On a Side Note…

See another CRM2 Nexus Notes Quarterly article that may be of interest to you.

No posts found.

On a Side Note…

See another Foundations & Endowments Nexus Notes Quarterly article that may be of interest to you.

No posts found.

On a Side Note…

See another Human Interest Nexus Notes Quarterly article that may be of interest to you.

It’s About Time

Topic:
Human Interest
Excerpt:
Over the last 25 years, we have written frequently about time. In fact, in 2010, our annual client presentation carried the same title as this article

On a Side Note…

See another Inside Nexus Nexus Notes Quarterly article that may be of interest to you.

A Virtual Nexus Welcome

Topic:
Inside Nexus
Excerpt:
We are excited to welcome Preethi Khatri Chetri to Nexus.

On a Side Note…

See another Investments Nexus Notes Quarterly article that may be of interest to you.

Uncertainty… Who Needs It? Apparently, We Do.

Topic:
Investments
Excerpt:
It is not exactly a revelation to say that uncertainty contributes to stress. In “normal” times – take 2019, for example – three common sources of

On a Side Note…

See another Pearls of Wisdom Nexus Notes Quarterly article that may be of interest to you.

China’s Larger Role in the World; Immortality in a Test Tube

Topic:
Pearls of Wisdom
Excerpt:
Reading is one of the principal occupations in our profession. As we digest a wide range of material, interesting ideas and surprising facts – some

On a Side Note…

See another Tax Planning Nexus Notes Quarterly article that may be of interest to you.

The (U.S.) Taxman Cometh

Topic:
Tax Planning
Excerpt:
Like the medical patient who expects to endure a fair bit of poking, probing and prodding from the doctor, clients of financial providers have had to

On a Side Note…

See another Wealth Planning Nexus Notes Quarterly article that may be of interest to you.

From the Editor: Happy New *Planning* Year

Topic:
Wealth Planning
Excerpt:
As the weather cools and the leaves begin to change colour, it seems to me that fall is the more natural start of a new year compared to the start of